Added 26/08/09: An open label, randomised, study to assess the efficacy and safety of Zenapax (daclizumab) or a single high dose of Anti-Thymocyte Globulin (ATG-Fresenius) for the prevention of acute rejection in patients receiving de novo simultaneous pancreas kidney transplantation treated with CellCept, Neoral and corticosteroids.

Trial Profile

Added 26/08/09: An open label, randomised, study to assess the efficacy and safety of Zenapax (daclizumab) or a single high dose of Anti-Thymocyte Globulin (ATG-Fresenius) for the prevention of acute rejection in patients receiving de novo simultaneous pancreas kidney transplantation treated with CellCept, Neoral and corticosteroids.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2009

At a glance

  • Drugs Antithymocyte globulin; Ciclosporin; Daclizumab; Mycophenolate mofetil; Prednisone
  • Indications Kidney-pancreas transplant rejection
  • Focus Therapeutic Use
  • Acronyms COMPAS
  • Most Recent Events

    • 06 Sep 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top